Oncology professionals attend a session at the 2023 ASCO Annual Meeting. (photo: © ASCO/Todd Buchanan)
Physicians and scientists from Winship Cancer Institute of Emory University will present new cancer research findings and offer expert perspectives as session leaders at the world's largest clinical cancer research meeting, the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 – June 4.
This year’s meeting will feature more than 200 sessions complementing the theme, “The Art and Science of Cancer Care: From Comfort to Cure.” The 37 Winship presentations – a mix of oral and poster abstracts, case-based panels, clinical science symposia and education sessions – include studies that evaluate targeted, repurposed and immunotherapy drugs; biomarkers and artificial intelligence to optimize treatment selection and patient care; air pollution and lung cancer risk; and a drug to prevent hearing loss in patients receiving cisplatin-based chemoradiation.
Several Winship abstracts selected for oral presentation will be the first to report new data from national and international cancer clinical trials. In his plenary session presentation featured in the Annual Meeting Press Program, Winship Executive Director Suresh Ramalingam, MD, FACP, FASCO, will deliver primary results of the phase 3 LAURA study, which evaluated osimertinib after chemoradiotherapy in patients with stage III epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Kevin Kalinsky, MD, MS, director of the Glenn Family Breast Center at Winship, will present two oral abstracts: (1) new insights from the RxPONDER study correlating serum anti-Müllerian hormone levels with premenopausal patients most likely to benefit from adjuvant breast cancer chemotherapy; and (2) the primary outcome of the phase 3 postMONARCH study evaluating the addition of abemaciclib to fulvestrant in certain patients with metastatic breast cancer. Jane L. Meisel, MD, associate professor of hematology and medical oncology, will present results from the iSPY2.2 study showing rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in patients with locally advanced breast cancer.
As part of the meeting, Andrew Hearn, MD, MSCI, a PG2 internal medicine resident at St. Francis – Emory Healthcare in Columbus, Georgia, received an ASCO Annual Meeting Merit Award from Conquer Cancer, the ASCO Foundation. The award provides monetary support and complimentary meeting registration for Hearn to present his first-author poster abstract, “Demographic trends and outcome measures found in randomized controlled trials of wellness interventions among medical trainees: A systematic review.”